Photo: A Healthy Point of View podcast

“The Molecule of Peace”: Dr. Tyler LeBaron's Case That the Active Ingredient in Hydrogen Water Was Never the Alkaline — It Was the Gas

The episode title asked the question outright: “The Truth About Hydrogen Water: Scam or Health Breakthrough?” Dr. Tyler LeBaron's answer, over 95 minutes on Sammy Tejada's A Healthy Point of View podcast, was essentially: both. The scam, he argues, is the word “alkaline.” The breakthrough candidate is the gas dissolved in the water — molecular hydrogen, the smallest molecule in biology, which he says slips through every membrane in the body, including the inner membrane of the mitochondria, and nudges those mitochondria to protect themselves.

LeBaron is not a medical doctor — he is a PhD researcher, and the distinction matters for how his claims should be read. He took his doctorate in animal physiology at Comenius University in Bratislava, Slovakia, after a master's at Southern Utah University, where he now teaches. A biochemistry professor handed him the field's founding paper in 2009 — a 2007 Nature Medicine study showing hydrogen selectively neutralized the most destructive free radical in biology — and he has worked on hydrogen ever since. In 2013, after a research internship at Nagoya University in Japan, he founded the Molecular Hydrogen Institute, a nonprofit that has become the field's main English-language clearinghouse. PubMed indexes 52 papers under his name; his own count, including chapters and non-indexed work, runs past 80.

The claim in one molecule

Hydrogen gas — H2 — is two hydrogen atoms, the lightest and smallest molecule there is. LeBaron's case rests on three linked claims.

First, it goes everywhere. “Once hydrogen gas gets to the cell membranes, it's able to penetrate the cell membranes very easily and reach subcellular compartments like the nucleus, the mitochondria,” he told Tejada. “It can penetrate these membranes, including the inner mitochondrial membrane, very easily.” Drink hydrogen water and hydrogen shows up in your breath within about two minutes, he noted — it reaches the brain and other organs on the same timescale. No transporter, no receptor, no blood-brain barrier problem.

Second, it is selective. The 2007 paper's central finding was that H2 reacts with the hydroxyl radical — the most cytotoxic oxidant in the body, the one with no detox enzyme — while leaving alone the reactive oxygen species the body uses for signaling, like superoxide, hydrogen peroxide, and nitric oxide. “Hydrogen is not merely a radical scavenger,” LeBaron said. “If you put hydrogen gas in the same compartment as important free radicals like nitric oxide or superoxide, there'd be no reaction.” That selectivity is his answer to the obvious objection: why don't ordinary antioxidants, taken at high doses, do the same thing? His reply cuts the other way — conventional antioxidants, he argued, can blunt the benefits of exercise itself: “The data shows that by taking antioxidants, not only do you slow down recovery, but you actually impair mitochondrial biogenesis.”

Third, it signals rather than scavenges. Hydrogen leaves the body within about an hour, yet effects in studies persist far longer, which pushed LeBaron and the field toward a signaling explanation: mild, hormetic activation of the Nrf2 pathway — the master switch for more than 200 protective proteins and enzymes — calibrated rather than forced. “It's regulating things,” he said. “It's helping the cells go back to homeostasis.” His boldest formulation: “Molecular hydrogen appears to act as an exercise mimetic, and you may even see increases in mitochondrial biogenesis.”

The mitochondria paper

The strongest single piece of mechanism evidence arrived in 2025, in Redox Biology, from the Nagoya group LeBaron still publishes with. The team reported that H2 directly targets the Rieske iron-sulfur protein — a working component of complex III, one of the five protein machines in the mitochondrial electron transport chain. In their experiments, hydrogen suppressed complex III activity within two minutes, promoted breakdown of the Rieske protein within the hour, and switched on the mitochondrial unfolded protein response — the organelle's internal quality-control and stress-signaling program.

If that finding holds up, it reframes the whole field: hydrogen would not be an antioxidant in the vitamin-C sense at all, but a mild mitochondrial stressor that provokes the cell's own defenses — hormesis at the level of the electron transport chain. That is a candidate mechanism from one strong laboratory, not settled science, and the article's evidence check below treats it that way.

The human evidence he can point to

LeBaron's flagship human trial, as lead author, is a 24-week randomized, double-blind, placebo-controlled study of high-concentration hydrogen-rich water in 60 adults with metabolic syndrome, published in 2020. The hydrogen group saw significant reductions in blood cholesterol and glucose and an improvement in hemoglobin A1c, alongside better inflammatory markers. It is one of the longer and more rigorous trials in the field — and it is still a single 60-person trial awaiting independent replication.

Around it sit smaller pieces: a pilot trial in fatty liver disease showing reduced liver fat and improved enzymes, and a second fatty-liver trial whose results were mostly favorable trends that did not reach significance; a trial of hydrogen plus PQQ in 34 older adults with mild cognitive impairment, aimed squarely at mitochondrial biomarkers; and work in athletes, including a 2025 trial in elite female athletes. In the episode, LeBaron also cited a Japanese trial of 2% hydrogen inhalation after cardiac arrest, describing survival of about 85% versus 61%. The underlying trial — HYBRID II, published in eClinicalMedicine in 2023 — did report those survival numbers, but survival was a secondary outcome; the trial's primary outcome, good neurological recovery, favored hydrogen without reaching statistical significance, and the study stopped early at 73 patients. Promising signal, not proof — and worth stating precisely, because this is the kind of claim that gets quoted without its caveats.

The firefighter question

The exchange most personal to this site's audience came when Tejada — who spent twelve years as a firefighter-paramedic — asked what hydrogen might mean for first responders breathing smoke for a living. LeBaron's answer: “By taking molecular hydrogen on a daily basis, you're sort of priming your cells for protection, so you can have a higher level of mitochondria function, higher resilience to stress.” He pointed to studies of hydrogen protecting against smoke-related carcinogenic exposures in animal models. That is a plausible-mechanism answer, not a demonstrated outcome in firefighters — no trial has tested it in that population — but it captures why he thinks the mitochondria are the right place to look for occupational resilience.

Near the end of the episode, LeBaron made a disclosure of his own: after more than a decade of, in his words, “not selling a product — just talking and educating about molecular hydrogen,” he was preparing to promote an inhalation device he helped develop and patented, designed to deliver hydrogen at clinical-study doses without the flammability risk that comes with hydrogen above about 4% concentration. That device is InhaleH2, where he is co-founder and chief scientific officer (see disclosure below). He calls hydrogen “the molecule of peace,” and closed on it: “Many wars have been fought over water, but I think that peace, real peace, will be found over hydrogen.”

The takeaway

Strip the marketing away and LeBaron's position is narrower and more defensible than the hydrogen-water hype around it: the alkaline in “alkaline water” was never the active ingredient; dose matters and most consumer products cannot deliver or retain one; and hydrogen's real interest lies in what it provokes — a calibrated stress signal centered on the mitochondria — rather than what it neutralizes. The mitochondria-specific mechanism now has a named molecular target to test, the human trials are real but small, and the field's most-cited researcher-evangelist now also sells the delivery device, which readers should weigh alongside his science. The honest summary is the one his own publication record supports: a genuinely interesting molecule, a plausible mitochondrial mechanism, promising early human signals — and a verdict that still belongs to larger, independent trials that have not yet been run.

Disclosure: Dr. Tyler LeBaron is a PhD researcher, not a medical doctor. He is founder and executive director of the Molecular Hydrogen Institute and co-founder and chief scientific officer of InhaleH2, a hydrogen-inhalation device company, and a named inventor on its patents. He was a guest on A Healthy Point of View, the podcast hosted by this site's founder, Sammy Tejada; this article covers that interview and his published research. It is not medical advice, and no hydrogen product is endorsed here.

Where the evidence stands

• Established: Hydrogen really does diffuse freely through cell membranes, the blood-brain barrier, and mitochondrial membranes — a matter of basic molecular physics, consistent with hydrogen appearing in exhaled breath within minutes of drinking hydrogen water. The field's founding result (Ohsawa et al., Nature Medicine 2007) — selective reaction with the hydroxyl radical in cell and animal models — is real and heavily cited. The safety record across human hydrogen studies is consistently benign, and dissolved hydrogen in water holds FDA GRAS status. The chemistry hazard is engineering, not pharmacology: inhaled hydrogen is flammable above roughly 4%.
• Preliminary: The metabolic-syndrome results come from one 24-week, 60-person trial (LeBaron's own) that has not been independently replicated at scale. The fatty-liver evidence is mixed — one positive pilot, one trial of mostly non-significant trends. The Rieske-protein mechanism is a single laboratory's 2025 finding in animal and cell systems. An independent 2023 review of 81 clinical trials (Johnsen et al.) found “positive indications” across several disease areas but described a literature of small, short, heterogeneous trials using surrogate endpoints — blood markers and symptom scores rather than hard clinical outcomes — with a visible share of authors tied to hydrogen product companies. HYBRID II's survival difference was a secondary outcome in an early-stopped trial whose primary outcome missed significance.
• Contested: The original scavenging story has a standing chemistry critique: the hydroxyl radical reacts almost instantly with whatever is nearest, so trace amounts of hydrogen may be too dilute to intercept much of it directly — one reason the field, LeBaron included, now leans on signaling and hormesis instead. His own co-authored 2022 work contains the field's most uncomfortable result: in cell culture, hydrogen enhanced proliferation of several cancer cell lines — the ones with strong mitochondrial stress responses — a reminder that “supports mitochondria” is not universally benign and that context decides the effect. The claim that hydrogen is an “exercise mimetic” that increases mitochondrial biogenesis in humans is an extrapolation from animal, cell, and biomarker data, not a demonstrated human outcome. And no regulator has approved hydrogen therapy for any condition.